key: cord-0893873-9jzssozq
authors: Jiang, Debbie; Portuguese, Andrew Jay; Weatherford, Amanda; Garcia, David; Gernsheimer, Terry
title: Platelet trends after Covid‐19 vaccination in patients with chronic or persistent immune thrombocytopenia
date: 2021-10-19
journal: Am J Hematol
DOI: 10.1002/ajh.26366
sha: cba9d78285140bf9993d339d40f9cdb9100755ca
doc_id: 893873
cord_uid: 9jzssozq

nan

To the Editor:

The association between immune thrombocytopenia (ITP) and the Covid-19 vaccine drew national attention when The New York Times reported in January 2021 that a Florida physician died from a hemorrhagic stroke after developing ITP within 2 weeks of vaccination. 1 Shortly thereafter, a review of the Vaccine Adverse Event Reporting System database described 20 cases of Covid-19 vaccine-associated thrombocytopenia, including 1 with a prior history of known ITP. 2 These observations raised concerns regarding risks of ITP recrudescence with immunization and furthered hesitancy among patients with chronic ITP. Adherence to vaccinations against influenza and pneumococcus are known to be suboptimal in patients with autoimmune disease, and a recent survey of 1266 patients with autoimmune or inflammatory rheumatic disease reported that only 54.2% were willing to be vaccinated against Covid-19. 3 In this context, hematologists have been tasked with providing clear messaging regarding benefits of vaccination and guidance on peri-immunization platelet count monitoring. However, little data exist on platelet counts and rates of ITP exacerbation in the post-immunization period among those with a history of chronic or persistent ITP. This single-center retrospective observational study evaluates the platelet trends and clinical outcomes of 34 patients with chronic or persistent ITP after receiving a 2-dose vaccination series against Covid-19. Potential subjects were identified among patients evaluated at the Seattle Cancer Care Alliance, the outpatient hematology site for the University of Washington hospital system, with an ICD-10 diagnosis code of D69.3 for "Immune thrombocytopenic purpura." Eligi- to 6 weeks after completion of the vaccination series were recorded. If multiple post-vaccination platelet counts were obtained, the lowest value was used for analysis. Subjects were contacted to confirm vaccination details if these were not completely recorded within the electronic medical record. One subject was described in a previously published case report. 4 We also contributed data from this subject and 12 others to a multicenter retrospective observational study 5 ; outcomes in these subjects are described in additional detail and with further follow-up data here.

A total of 34 subjects were included. The average age was 60. Fourteen patients had a post-vaccination platelet decrease resulting in a count of less than 50 Â 10 9 /L and four had a count less than 10 Â 10 9 /L. Platelet nadir below 50 Â 10 9 /L occurred after dose 1 in 50% (7/14), after dose 2 in 28.6% (4/14), and after both doses of vaccine in 21.4% (3/14). Six of the 14 and 3 of the 4 with platelet counts less than 50 Â 10 9 /L and 10 Â 10 9 /L, respectively, received intervention for post-vaccination thrombocytopenia. The eight patients who did not receive intervention had a significantly lower median baseline compared to the overall cohort (50.5 Â 10 9 /L vs 86.0 Â 10 9 /L, p = .01) and platelet counts at last follow up remained stable from baseline at a median of 53 Â 10 9 /L (IQR 41.0-104.8 Â 10 9 /L). The patient who did not receive intervention for platelet count less than 10 Â 10 9 /L after vaccination had pre-vaccination counts consistently in the single digits, with a baseline count of 5 Â 10 9 /L. With the advent of widespread Covid-19 vaccination, sporadic cases of immunization-related ITP recrudescence raised safety concerns among those with a history of ITP. We report that among a cohort of patients managed at a tertiary care center for chronic or persistent ITP, half had a decrease in platelet count of 20% or more from baseline while half had no change or an increase. There was a trend toward a decrease in platelet count following dose 1 and no difference in platelet count following dose 2. Six patients (17.6%) required intervention, but for two of the six, worsening thrombocytopenia may have been related to recent dose adjustments. Nearly the same number received a reduction in the intensity of their ITP therapy during the study period. No patients experienced severe adverse events or required hospitalization during the study period. ACKNOWLEDGMENT DJ receives support from an institutional training grant from the National Heart, Lung, and Blood Institute (T32 HL007093). 

Weatherford. All authors contributed to the study design and interpretation of results. Debbie Jiang was responsible for drafting the manuscript and data analysis. Andrew Jay Portuguese, Amanda

Weatherford, David Garcia, and Terry Gernsheimer contributed to critical revision.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

National Heart, Lung, and Blood Institute, T32 HL007093. 

Doctor's death after covid vaccine is being investigated. The New York Times

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases

Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination

SARS-CoV-2 vaccination and immune thrombocytopenia in de novo and pre-existing ITP patients